A novel vaccine designed to target one of the most common cancer-driving mutations in patients with pancreatic and colorectal cancer is showing promising results
Researchers in Nature Medicine reported that the vaccine, called ELI-002 2P, offers fresh hope for individuals affected by pancreatic and colorectal cancer, following promising outcomes in a recent clinical trial.
Pancreatic cancer is one of the most lethal cancers, with a five-year survival rate of about 13 per cent, according to the American Cancer Society. It typically causes no symptoms until it has already spread. Surgery, radiation and chemotherapy can extend survival but rarely provide a cure.
According to them, the vaccine can safely and effectively train the immune system to recognise and fight cancer-driving mutations.
Developed by researchers from institutions across the US, the vaccine targets mutations in the KRAS gene. These mutations are linked to 93 per cent of pancreatic cancers and 50 per cent of colorectal cancers.
Coupled with a delivery system that takes the vaccine’s active agent straight to the lymph nodes, the treatment is designed to precisely target parts of the immune system where a variety of immune cells are held.
The vaccine was tested on 20 people recovering from pancreatic cancer and five people recovering from colorectal cancer. They had all had surgery to remove tumours, but in subsequent tests, they were showing signs that the cancer was likely to return.
Additional trials and testing will be necessary to fully evaluate the risks and benefits, but considering the high recurrence and mortality rates of pancreatic and colorectal cancers, there’s strong evidence here that this vaccine could add years of health to people’s lives.
The researchers also saw positive signs of the vaccine training the immune system to fight other types of cancer mutations, too, so there’s the potential for it to be even more useful in efforts to improve treatments going forward.
In a reaction, Zev Wainberg, a medical oncologist at the University of California, Los Angeles, said, “This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited.”
Targeting KRAS has long been considered one of the difficult challenges in cancer therapy. But the researchers were able to show that the ELI-002 2P vaccine can safely and effectively train the immune system to recognise and fight cancer-driving mutations.
WARNING: If You Are Not 18+, Don’t Click The Link Below 👇🫣
https://abnormalitylovingmammal.com/kx6iepv2qm?key=6c14bd1d68e1eba721851f19778f5efe
https://poawooptugroo.com/4/8902554
Please don’t forget to “Allow the notification” so you will be the first to get our gist when we publish it.
Drop your comment in the section below, and don’t forget to share the post.
Never Miss A Single News Or Gist, Kindly Join Us On WhatsApp Channel:
https://whatsapp.com/channel/0029Vad8g81Eawdsio6INn3B
Telegram Channel:
https://t.me/gistsmateNG
